Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:

Subscribers log in here

Devices for percutaneous closure of a secundum atrial septal defect


Atrial septal defect (ASD) is the most common congenital lesion in adults after bicuspid aortic valve, while a patent foramen ovale (PFO) can be detected in approximately 30 percent of normal adult hearts.

Percutaneous device closure is an effective, safe, and commonly employed alternative to surgical closure in patients with ostium secundum ASDs and PFOs that have appropriate indications and anatomic characteristics. The limited data comparing surgical and percutaneous closure of a secundum ASD suggest that the rates of procedural success may be comparable or possibly better with surgery, but that the rate of complications and length of hospital stay may be reduced with the percutaneous approach.

This topic will review the characteristics of the Amplatzer, Gore Helix, and CardioSEAL devices and other devices that are still investigational. Atrial septal defect closure is indicated largely to treat hemodynamic effects. PFO closure is indicated for platypnea-orthodeoxia syndrome; its efficacy for stroke prevention is not established. Indications for and efficacy of percutaneous repair of ASDs and PFOs and associated complications are presented separately. (See "Management of atrial septal defects in adults" and "Management and outcome of isolated atrial septal defects in children" and "Patent foramen ovale" and "Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults".)


The United States Food and Drug Administration's Center for Devices and Radiological Health approved the Amplatzer Septal Occluder (figure 1) for percutaneous secundum ASD closure in December 2001 [1]. The Gore Helix Septal Occluder was approved for percutaneous closure of secundum ASDs in August 2006. Another device, the CardioSEAL Septal Occlusion System has been used off-label for ASD and PFO closure but is FDA approved for use only for closure of certain complex ventricular septal defects.

The humanitarian device exemptions for two patent foramen occluder devices, the CardioSEAL STARFlex Septal Occlusion system and the Amplatzer PFO occluder were withdrawn in October 2006. These devices are now available in the United States for investigational use only.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2014. | This topic last updated: Nov 19, 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
  1. Schwetz BA. From the Food and Drug Administration. JAMA 2002; 287:578.
  2. Thanopoulos BD, Laskari CV, Tsaousis GS, et al. Closure of atrial septal defects with the Amplatzer occlusion device: preliminary results. J Am Coll Cardiol 1998; 31:1110.
  3. Chan KC, Godman MJ, Walsh K, et al. Transcatheter closure of atrial septal defect and interatrial communications with a new self expanding nitinol double disc device (Amplatzer septal occluder): multicentre UK experience. Heart 1999; 82:300.
  4. Fischer G, Kramer HH, Stieh J, et al. Transcatheter closure of secundum atrial septal defects with the new self-centering Amplatzer Septal Occluder. Eur Heart J 1999; 20:541.
  5. Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol 2002; 39:1061.
  6. Jones TK, Latson LA, Zahn E, et al. Results of the U.S. multicenter pivotal study of the HELEX septal occluder for percutaneous closure of secundum atrial septal defects. J Am Coll Cardiol 2007; 49:2215.
  7. Pedra CA, Pihkala J, Lee KJ, et al. Transcatheter closure of atrial septal defects using the Cardio-Seal implant. Heart 2000; 84:320.
  8. Carminati M, Chessa M, Butera G, et al. Transcatheter closure of atrial septal defects with the STARFlex device: early results and follow-up. J Interv Cardiol 2001; 14:319.
  9. Jux C, Bertram H, Wohlsein P, et al. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: development and preclinical evaluation of the BioSTAR device. J Am Coll Cardiol 2006; 48:161.
  10. Mullen MJ, Hildick-Smith D, De Giovanni JV, et al. BioSTAR Evaluation STudy (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation 2006; 114:1962.
  11. Zamora R, Rao PS, Lloyd TR, et al. Intermediate-term results of Phase I Food and Drug Administration Trials of buttoned device occlusion of secundum atrial septal defects. J Am Coll Cardiol 1998; 31:674.
  12. Aeschbacher BC, Chatterjee T, Meier B. Transesophageal echocardiography to evaluate success of transcatheter closure of large secundum atrial septal defects in adults using the buttoned device. Mayo Clin Proc 2000; 75:913.
  13. Agarwal SK, Ghosh PK, Mittal PK. Failure of devices used for closure of atrial septal defects: mechanisms and management. J Thorac Cardiovasc Surg 1996; 112:21.
  14. Das GS, Voss G, Jarvis G, et al. Experimental atrial septal defect closure with a new, transcatheter, self-centering device. Circulation 1993; 88:1754.
  15. Rickers C, Hamm C, Stern H, et al. Percutaneous closure of secundum atrial septal defect with a new self centering device ("angel wings"). Heart 1998; 80:517.
  16. Banerjee A, Bengur AR, Li JS, et al. Echocardiographic characteristics of successful deployment of the Das AngelWings atrial septal defect closure device: initial multicenter experience in the United States. Am J Cardiol 1999; 83:1236.
  17. Sievert H, Babic UU, Hausdorf G, et al. Transcatheter closure of atrial septal defect and patent foramen ovale with ASDOS device (a multi-institutional European trial). Am J Cardiol 1998; 82:1405.
  18. Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. (Accessed on May 04, 2007).